Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 6, Issue 6, Pages 306-307Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2009.69
Keywords
-
Categories
Ask authors/readers for more resources
on the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available